Patients with metastatic castration-resistant prostate cancer now have a new treatment option with the U.S. Food and Drug Administration’s (FDA’s) recent approval of Pluvicto (lutetium Lu 177 vipivotide tetraxetan). The radiopharmaceutical medication, from Novartis...
CAMBRIDGE, MA — On Feb. 23, Voluntis, an Aptar Pharma company and leader in digital therapeutics, announced a partnership with Tilak Healthcare, a digital therapeutics company specializing in clinically validated medical mobile apps for chronic diseases. Under this...
WASHINGTON, DC — Researchers have developed a new image reconstruction approach that could contribute to better breast cancer detection. The deep learning algorithm overcomes a major hurdle in multi-modality imaging by allowing images to be recovered in real time....